Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Phase 2LaromestrocelNeutral

AI Analysis

Summary

Longeveron announced topline results from the ELPIS II Phase 2b clinical trial evaluating Laromestrocel for hypoplastic left heart syndrome. The article provides no details regarding trial outcomes, efficacy data, or patient population.

Clinical Trial Data

Phase

Importance:6/10

Sentiment:

0.00

Phase 2btopline resultsHLHScell therapy

Related Companies

$LGVN

Read the original article

Published by GlobeNewswire Clinical Studies on September 16, 2026 9:27 PM

Read Original